Wyeth Begins Marketing and Distributing BeneFIX in Europe

Collegeville, Pennsylvania (ots/PRNewswire) -

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced
today that it has assumed all marketing and distribution rights to
BeneFIX(R) Coagulation Factor IX (Recombinant) in Europe. This
transfer of responsibility follows the planned June 30, 2007
conclusion of a 10-year distribution rights agreement between Baxter
Healthcare Corporation and Genetics Institute. Genetics Institute was
acquired by Wyeth in 1996. Representatives of Wyeth and Baxter have
worked closely together to ensure a structured transition between
companies and an uninterrupted supply of BeneFIX to people with
hemophilia B.

"We are pleased to broaden Wyeth's range of therapeutic offerings
for the hemophilia community in Europe. We also have plans-pending
European regulatory approval-to introduce new convenience
enhancements to BeneFIX later this year," says Cavan Redmond,
Executive Vice President & General Manager, BioPharma Business Unit
at Wyeth Pharmaceuticals.

Wyeth now manufactures and markets recombinant products for both
hemophilia A and B in Europe, which are rare bleeding disorders.

In May 2007, Wyeth Pharmaceuticals received a positive opinion
from the Committee for Medicinal Products for Human Use, the
scientific committee of the European Medicines Agency, on new
convenience enhancements to BeneFIX. The product enhancements are: a
2000 IU dosage strength vial, a needleless reconstitution device, a
prefilled diluent syringe and a low 5 mL diluent volume for all
dosage strengths.

Hemophilia B is a rare, inherited blood clotting disorder. People
with hemophilia B are deficient in a key protein- factor IX- which is
vital in the clotting mechanism to prevent bleeding. Hemophilia B is
characterized by spontaneous hemorrhages or prolonged bleeding,
typically into joints and soft tissue. Patients with hemophilia B are
dependent on protein replacement therapy with factor IX.

About BeneFIX

BeneFIX is indicated for the control and prevention of hemorrhagic
episodes in patients with hemophilia B (congenital factor IX
deficiency or Christmas disease), including control and prevention of
bleeding in surgical settings.

BeneFIX is not indicated for the treatment of other factor
deficiencies (e.g., factors II, VII, VIII and X) nor the treatment of
hemophilia A patients with inhibitors to factor VIII, nor the
reversal of coumarin-induced anticoagulation, nor the treatment of
bleeding due to low levels of liver-dependent coagulation factors.

Important Safety Information
-- As with the intravenous administration of any protein product, common
adverse reactions may include headache, fever, chills, flushing,
nausea, vomiting or tiredness.
-- BeneFIX may be contraindicated in patients with a known history of
hypersensitivity to hamster protein.
-- Allergic-type hypersensitivity reactions, including anaphylaxis, have
been reported for all factor IX products. Patients should be informed
of the early symptoms and signs of hypersensitivity reactions.
Patients should discontinue use of the product and contact their
health care provider immediately and/or seek emergency care if any
hypersensitivity reactions occur.

About ReFacto

ReFacto(R) Antihemophilic Factor (Recombinant) is indicated for
the control and prevention of hemorrhagic episodes and for surgical
prophylaxis and for short-term routine prophylaxis to reduce the
frequency of spontaneous bleeding episodes in patients with
hemophilia A. The effect of regular routine prophylaxis on long-term
morbidity and mortality is unknown.

Important Safety Information
-- As with the intravenous administration of any protein product, adverse
reactions may include headache, fever, chills, flushing, nausea,
vomiting, tiredness, or symptoms of allergic reactions.
-- The remote possibility exists for hypersensitivity to non-human
mammalian proteins. Known hypersensitivity to mouse or hamster
proteins may be a contraindication to the use of ReFacto.
-- Allergic reactions such as hives, itching, difficulty breathing, rapid
heart rate, light-headedness and anaphylaxis have been reported for
all factor VIII products. Patients should discontinue use of the
product and contact their health care provider immediately and/or seek
emergency care if any of these symptoms occur.

Please see Prescribing Information for BeneFIX and ReFacto at
www.hemophiliavillage.com.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products
in the areas of women's health care, infectious disease,
gastrointestinal health, central nervous system, inflammation,
transplantation, hemophilia, oncology, vaccines and nutritional
products. Wyeth is one of the world's largest research-driven
pharmaceutical and health care products companies. It is a leader in
the discovery, development, manufacturing and marketing of
pharmaceuticals, vaccines, biotechnology products and
non-prescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal
Health.

The statements in this press release that are not historical facts
are forward-looking statements based on current expectations of
future events and are subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include the
inherent uncertainty of the timing and success of, and expense
associated with, research, development, regulatory approval and
commercialization of our products, including with respect to our
pipeline products; government cost-containment initiatives;
restrictions on third-party payments for our products; substantial
competition in our industry, including from branded and generic
products; data generated on our products; the importance of strong
performance from our principal products and our anticipated new
product introductions; the highly regulated nature of our business;
product liability, intellectual property and other litigation risks
and environmental liabilities; uncertainty regarding our intellectual
property rights and those of others; difficulties associated with,
and regulatory compliance with respect to, manufacturing of our
products; risks associated with our strategic relationships; economic
conditions including interest and currency exchange rate
fluctuations; changes in generally accepted accounting principles;
trade buying patterns; the impact of legislation and regulatory
compliance; risks and uncertainties associated with global operations
and sales; and other risks and uncertainties, including those
detailed from time to time in our periodic reports filed with the
Securities and Exchange Commission, including our current reports on
Form 8-K, quarterly reports on Form 10-Q and annual report on Form
10-K, particularly the discussion under the caption "Item 1A, Risk
Factors." The forward-looking statements in this press release are
qualified by these risk factors. We assume no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.

Web site: http://www.wyeth.com
http://www.hemophiliavillage.com

ots Originaltext: Wyeth Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media Contacts, Natalie deVane of Wyeth Pharmaceuticals,
+1-484-865-5139, or Douglas Petkus of Wyeth, +1-973-660-5218, or
Investor, Justin Victoria of Wyeth, +1-973-660-5340